Open Access

The effect of an alternative chromosome 17 probe on fluorescence in situ hybridization for the assessment of HER2 amplification in invasive breast cancer

  • Authors:
    • Zhigao Xu
    • Peipei Xu
    • Wei Fan
    • Ben Huang
    • Qingyuan Cheng
    • Zheng Zhang
    • Ping Wang
    • Mingxia Yu
  • View Affiliations

  • Published online on: July 9, 2019     https://doi.org/10.3892/etm.2019.7756
  • Pages: 2095-2103
  • Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Fluorescent in situ hybridization (FISH) is commonly used to determine the ratio of human epidermal growth factor receptor 2 (HER2) to centromere enumeration probe for chromosome 17 (CEP17), which further determines HER2 gene status in breast cancer. However, due to copy number alteration in CEP17, inaccurate diagnoses can occur. The current study was performed to investigate the diagnostic value of an alternative CEP17 reference probe for HER2 status in invasive breast cancer. A higher‑order repeat in the centromeric region of chromosome 17 was identified and an alternative probe (SCEP17) was subsequently prepared. Karyotype analysis of peripheral blood was used to detect SCEP17 probe specificity. Using a HER2/CEP17 probe, karyotype analysis revealed two strong green signals at the centromere of chromosome 17 and one weaker signal at the other centromere. However, two strong hybridization signals at the centromere of chromosome 17 were observed when the HER2/SCEP17 probe was used. In the 425 patients with invasive breast cancer, no statistical difference was observed between HER2/SCEP17 and HER2/CEP17 when detecting HER2 gene amplification (P=0.157). However, in terms of copy number, the SCEP17 probe exhibited a reduced number compared with the conventional CEP17 probe (P<0.001). In conclusion, the HER2/SCEP17 probe may lead to increased accuracy HER2 status assessment in invasive breast cancer. However, a further large‑scale and prospective clinical trial is required for confirmation of the potential benefits of using the HER2/SCEP17 probe.

Related Articles

Journal Cover

September 2019
Volume 18 Issue 3

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Xu, Z., Xu, P., Fan, W., Huang, B., Cheng, Q., Zhang, Z. ... Yu, M. (2019). The effect of an alternative chromosome 17 probe on fluorescence in situ hybridization for the assessment of HER2 amplification in invasive breast cancer. Experimental and Therapeutic Medicine, 18, 2095-2103. https://doi.org/10.3892/etm.2019.7756
MLA
Xu, Z., Xu, P., Fan, W., Huang, B., Cheng, Q., Zhang, Z., Wang, P., Yu, M."The effect of an alternative chromosome 17 probe on fluorescence in situ hybridization for the assessment of HER2 amplification in invasive breast cancer". Experimental and Therapeutic Medicine 18.3 (2019): 2095-2103.
Chicago
Xu, Z., Xu, P., Fan, W., Huang, B., Cheng, Q., Zhang, Z., Wang, P., Yu, M."The effect of an alternative chromosome 17 probe on fluorescence in situ hybridization for the assessment of HER2 amplification in invasive breast cancer". Experimental and Therapeutic Medicine 18, no. 3 (2019): 2095-2103. https://doi.org/10.3892/etm.2019.7756